ClinicalTrials.gg
RecruitingNCT07030790Updated Jun 22, 2025

A Phase I Clinical Study of a Single Dose of KLA480

A Phase 1 interventional study of KLA480 injection and Placebo in Healthy Participants, sponsored by Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-22.

Sponsored by Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. (part of Sichuan Kelun Pharmaceutical Co.,Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Primary purpose:

To evaluate the safety and tolerability of KLA480 injection after a single subcutaneous injection in healthy participants.

Secondary purpose:

To evaluate the pharmacokinetic (PK) characteristics of KLA480 injection after a single subcutaneous injection in healthy participants.

Read the detailed description

This study was a single-center, randomized, double-blind, placebo-controlled, dose Escalation, phase I clinical study to evaluate the safety, tolerability and pharmacokinetic characteristics of KLA480 injection after a single subcutaneous injection in healthy Chinese participants.

The plan is to enroll 20 healthy participants in two dose groups: Group I (11.3 mg) and Group II (22.6 mg). Each dose group will includ 10 participants (at least 3 single-sex participants). Among them, 8 participants received the experimental drug KLA480 injection, and 2 participants received the placebo KLA480 injection simulator. Participants in different dose groups were successively enrolled. Based on the evaluation of acceptable tolerance and safety of participants in the former dose group, the researchers will discuss with the sponsor whether to carry out the next dose group. The "sentinel" method was used in each dose group, that is, 3 participants were enrolled in each dose group first, of which 2 participants received KLA480 injection, and 1 participant received placebo KLA480 injection simulator. Tolerance assessment will be performed 48 h after administration of the first 3 participants, and if the tolerance evaluation is acceptable, the remaining 7 participants in the current dose group will be enrolled (6 receiving the experimental drug and 1 receiving placebo).

02

Conditions studied

  • Healthy Participants

Keywords

  • Healthy
03

In context

Lead sponsor

This is the only study on the registry with Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants could understand and abide by the study process, voluntarily participate in the study, and sign the form in person;
  2. Healthy adult participants of both sexes aged 18 to 45 years (including boundary values);
  3. A body weight of at least 50.0 kg for men and 45.0 kg for women. in the range of 18.0-28.0 kg/m2 (including the boundary value);
  4. The results of vital signs, physical examination, laboratory examination, chest X-ray (anteroposterior), and were normal or abnormal with no clinical significance judged by the investigators;
  5. Any female or male participant of potential fertility must agree not to donate sperm or eggs from the date of sign informed consent form until 3 months after the last dose, must use an effective method, and before the last visit,participants must use nonpharmacologic contraceptive methods to prevent pregnancy or to impregnate a partner.

Exclusion criteria

Exclusion Criteria:

  1. Participants with a history of severe allergy or allergy to any component or vehicle components of rotigotin or other non-ergotamine dopamine agonists (pramipexole, ropinirole, piribedil, and apomorphine) ;
  2. Participants with a history of gastrointestinal, renal, hepatic, neurological, hematologic, endocrine, tumor, pulmonary, immune, psychiatric, or cardio-cerebrovascular diseases with clinical significance judged by the investigators;
  3. History of unexplained orthostatic hypotension, syncope or low systolic blood pressure;
  4. Participants with a history of acute infection or other acute diseases within 2 weeks before signing the form;
  5. Those who had unprotected sexual behavior within 2 weeks before signing the informed consent form;
  6. Participants who cannot tolerate venous puncture or have a history of fainting blood or fainting needles;
  7. Donating blood or massive blood loss (≥400 mL), or receiving blood transfusion/use of blood products within 3 months before signing the informed consent form;
  8. Participants who had undergone surgery that would affect the absorption, distribution, metabolism, or excretion of drug as judged by the investigators within 6 months before signing the informed consent form, or had undergone surgery within 4 weeks before the first dose of the trial drug, or planned to undergo surgery between signing the informed consent form and the last visit;
  9. Participated in any drug/device clinical trial and used the experimental drug/device within 3 months before signing the informed consent form;
  10. Those who had been vaccinated within 1 month before signing the informed consent form, or planned to be vaccinated between signing the informed consent form and the last visit;
  11. Strong or moderate inhibitors and/or inducers of liver metabolic enzymes (CYP1A2, CYP2C19, ) of rotigotin was using within 4 weeks before the first dose of the trial drug. Examples: Fluvoxamine, Fluconazole, Fluoxetine, ticlopidine, Ceritinib, atanavir, Adrasib, telithromycin, Clarithromycin, itraconazole, ketoconazole, posaconazole, voriconazole, indinavir, Nefinavir, ritonavir, Saquinavir, telanavir, Lopinavir, Nefaketozole, Cobirestat, Apalutamide, enzalutamide, Lumacato, Mitol Tam, ivoclib, phenytoin, carbamazepine, rifampicin, St John's wort;
  12. Who used any prescription drug, over-the-counter drug, vitamin product or Chinese herbal medicine within 2 weeks before the first dose of the trial drug;
  13. During the screening period, systolic blood pressure decreased ≥20 mmHg or diastolic blood pressure decreased ≥10 mmHg within 3 minutes from supine to upright position, or supine systolic blood pressure \< 100 mmHg;
  14. Participants with > 450 ms during the screening period;
  15. virus surface antigen, virus antibody, TPPA antibody, antibody test results are positive;
  16. Female participants with positive pregnancy results or in the lactation period;
  17. Had a history of drug abuse or drug use within 6 months before signing the informed consent form, or had a positive result of urine drug screening;
  18. Had a history of heavy drinking within 6 months before signing the informed consent form (heavy drinking was defined as drinking 14 units of alcohol per week: 1 unit = beer 285 mL, or spirits 25 mL, or wine 100 mL), or could not give up drinking from signing the informed consent form to the last visit, or had a positive result of alcohol breath test;
  19. Participants who had smoked more than 3 cigarettes per day within 3 months before signing the informed consent form, smoked or used tobacco products within 2 weeks before the first dose of the trial drug, or could not give up smoking between signing the informed consent form and the last visit, or had a positive result of tobacco screening test;
  20. Participants who consumed grapefruit or a drink containing grapefruit juice within 2 weeks before the first dose of the trial drug;
  21. Those who consumed chocolate, any food or drink containing caffeine (such as coffee, tea, milk tea, cola, red bull, etc.) or rich in xanthine (such as shiitake mushroom, silver carp, mulberry, seafood (silver beetle, white hairtail, oyster, white pomade, eel, etc.), animal organs (duck liver, chicken liver, pig large intestine, pig liver, beef liver, etc.) within 72 hours before the first dose of the trial drug;
  22. Those who have special dietary requirements and cannot follow the uniform diet during hospitalization;
  23. Participants with other factors considered by the investigator to be ineligible for the trial.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    KLA480 injection 11.3mg

    8 subjects receive KLA480 at a dose of 11.3mg and 2 subjects receive the same volume placebo

    Drug: KLA480 injection · Drug: Placebo

  • Experimental
    KLA480 injection 22.6mg

    8 subjects receive KLA480 at a dose of 22.6mg and 2 subjects receive the same volume placebo

    Drug: KLA480 injection · Drug: Placebo

Interventions

  • DrugKLA480 injection

    Subcutaneous injection,Single dose

  • DrugPlacebo

    Subcutaneous injection,Single dose

06

What researchers measure

Primary outcomes

  1. Safety and tolerability

    Safety and tolerability was assessed by the number of participants with adverse events (AE).

    Time frame: Collected from signing of informed consent until 43 days after a single dose.

Secondary outcomes

  1. Maximum peak plasma concentration (Cmax) [Pharmacokinetics]

    Samples will also be collected until 43 days after a single dose(samples will be collected in the morning). PK parameters will be assessed for plasma brexpiprazole and its metabolite(s) .

    Time frame: 43 days after a single dose.

  2. Time of Cmax (tmax) [Pharmacokinetics]

    Samples will also be collected until 43 days after a single dose(samples will be collected in the morning). PK parameters will be assessed for plasma brexpiprazole and its metabolite(s) .

    Time frame: 43 days after a single dose.

  3. Area under the concentration-time curve (AUC) from time zero to time "t" [Pharmacokinetics]

    Samples will also be collected until 43 days after a single dose(samples will be collected in the morning). PK parameters will be assessed for plasma brexpiprazole and its metabolite(s) .

    Time frame: 43 days after a single dose.

  4. AUC from time zero to infinity (AUC∞) [Pharmacokinetics]

    Samples will also be collected until 43 days after a single dose(samples will be collected in the morning). PK parameters will be assessed for plasma brexpiprazole and its metabolite(s) .

    Time frame: 43 days after a single dose.

  5. Terminal-phase elimination half-life (t1/2,z) [Pharmacokinetics]

    Samples will also be collected until 43 days after a single dose(samples will be collected in the morning). PK parameters will be assessed for plasma brexpiprazole and its metabolite(s) .

    Time frame: 90 days after a single dose.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Dec 2026, 19 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2025
First posted
Jun 22, 2025
StartActual
May 17, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Mar 1, 2027
Last update
Jun 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07030790
Responsible party
Sponsor
First posted
Jun 22, 2025
Start date
May 17, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Jun 22, 2025

Study contacts

Wei Qi
Contact
qiw@kelun.com
028-82339360

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion